This article is mentioned in:

Introduction

Serrated polyposis (SPP), which was previously known as hyperplastic polyposis, is characterized by the presence of multiple colorectal epithelial polyps with a serrated architecture, termed serrated (SE) polyps, as well as an increased predisposition to colorectal cancer (CRC) (1–3). SE polyps differ from adenomatous (AD) polyps and are comprised of various lesions, namely: hyperplastic polyps (HPs), non-dysplastic lesions with normal proliferation and architecture but elongated crypts with a saw-toothed appearance; sessile serrated adenomas (SSAs), lesions that present abnormal proliferation and architecture and may or may not include dysplasia; and traditional serrated adenomas (TSAs) that are dysplastic polyps with prominent serration (1,4–6). The presence of multiple SE polyps has also been associated with other hereditary conditions, namely serrated pathway syndrome or Jass syndrome (7–9).

It has been proposed that these SE lesions arise through the serrated pathway rather than through the adenoma-carcinoma sequence pathway (7,10–13). It has also been suggested that the HP is the precursor lesion in this pathway, with SSA as an intermediate step which then progresses to an adenocarcinoma with or without microsatellite instability (MSI or MSS, respectively). At the molecular level, SE lesions associated with those hereditary serrated syndromes share some genetic alterations, namely the presence of B-raf proto-oncogene, serine/threonine kinase (BRAF) mutations and the methylator phenotype, termed CpG island methylator phenotype (CIMP) (14–16), although these are also common to the sporadic SE lesions.

However, the analysis of SPP lesions has revealed specific features which are distinct from the SE lesions occurring in a sporadic context; accordingly, in SPP, HPs, TSAs and CRC are preferentially located in the proximal colon, i.e. proximal to the splenic flexure (17–19). Moreover, patients with SPP have previously been found to present extensive DNA methylation in the normal mucosa of the proximal colon (20), suggesting the involvement of widespread gene promoter methylation (CIMP) (7,14,21). This phenotype appears to be related to MutL homolog 1 (MLH1) methylation, which has been associated with MSI status, rather than O-6-methylguanine-DNA methyltransferase (MGMT) methylation. However, MSI appears to be less frequent in SPP lesions than in sporadic lesions (14,22). Similarly, SPP lesions also exhibited a lower frequency of Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations when compared with sporadic SE lesions (21,22). However, it was also found that most adenomas and CRCs from patients with SPP exhibited a classic morphology and that few of these had BRAF or KRAS mutations, although SE lesions presented a high frequency of mutations in these genes (22). Previous research has suggested that tumorigenesis associated with SPP may not necessarily follow the serrated pathway and may follow an alternate pathway, involving TSAs and tubulovillous adenomas (TVAs) as intermediate lesions that progress to MSS adenocarcinomas with KRAS mutations or even a traditional pathway with adenomatous polyposis coli (APC) mutations as the initiating events (10).

A review of published case studies of SPP reported that approximately 10–50% of patients with SPP have been described as having a family history of CRC (23). In agreement with these findings, several studies have described an increased risk of CRC in the first-degree relatives of probands diagnosed with SPP compared with the general population (2,17,18,24–28). These studies have contributed to the notion that there are SPP cases where heredity may play a role in the development of CRC and/or polyps. Indeed, another review on this subject reinforces the concept that familial SPP exists and also the importance of defining the genetic basis of familial SPP and of studying these families in a systematic manner (29).

Thus, in the present study, we aimed to characterize, at the clinical and molecular level, SE and AD lesions from a cohort of patients with SPP who had been stratified into two groups: patients with or without a family history of SPP and/or polyps/CRC in first-degree relatives, in order to elucidate the information available regarding this new SPP entity with an apparent hereditary component.

Patients and methods

Patients and specimens

Eighteen patients diagnosed with SPP according to the WHO diagnostic criteria (1) were included in this study: 12 patients with SPP associated with a family history of SPP and/or polyps/CRC (multiple or diagnosed at a young age) in first-degree relatives (designated herein as SPP-FHP/CRC) (11 index and one affected relative diagnosed simultaneously with the index patient), and 6 index patients without a family history of SPP/polyps/CRC (designated herein as sporadic SPP) from the familial colorectal cancer registry of the Portuguese Institute of Oncology of Lisbon Francisco Gentil (Lisbon, Portugal). No evidence of SPP and/or polyps/CRC was found in the first-degree relatives of the patients with sporadic SPP, either by regular colonoscopy examination or by the absence of symptoms. The patients were classified as presenting a family history of polyps in first-degree relatives (5/11), if at least one relative had been diagnosed with polyps at or under 52 years of age or with >10 polyps. We cannot exclude the possibility that some of these families, namely PH4 or PH6, may have Jass syndrome instead of SPP, due to the presence of a mixture of AD and SE lesions (7,9). All patients had developed >10 lesions prior to the date of recruitment.

Sixty-two lesions were included here: 1 hyperplastic colonic mucosa (HCM), 25 HPs, 8 TSAs, 11 SSAs, 1 adenomatous/serrated (AD/S) carcinoma (Ca), 1 serrated carcinoma (SCa), 8 tubular adenomas (TAs), 2 TVAs and 5 Ca. Two normal colonic mucosa (NCM) samples were also included in this study. Fresh colorectal lesions were obtained from colectomy or colonoscopy specimens from patients who underwent surgery or colonoscopy in the Portuguese Institute of Oncology of Lisbon Francisco Gentil. Sections from corresponding areas of the specimens submitted for diagnosis were divided into two parts: one was snap frozen in liquid nitrogen immediately after resection, while the other was formalin-fixed and paraffin-embedded.

Histological characterization, according to the WHO guidelines (1), was performed by experienced pathologists (R.F. and P.C.). The study was conducted in accordance with local ethical standards and in agreement with the Helsinki Declaration of 1975, as revised in 1983. Informed consent for diagnosis and additional investigational studies, which may result in improving the knowledge about the pathogenesis of the disease, was obtained from patients included in this study. Moreover, biological material used for DNA isolation was obtained from archival sections from colorectal adenomas and carcinomas specimens, submitted for diagnosis (histological classification) and derived from patients who underwent surgery or colonoscopy in the Portuguese Institute of Oncology of Lisbon Francisco Gentil; only somatic analysis was performed and samples are truly anonymized.

Methods

DNA isolation

DNA was isolated from fresh-frozen and/or paraffin-embedded tumor tissue and matched normal tissue. DNA was isolated from the paraffin-embedded tissues by proteinase K digestion, which was followed by phenol/chloroform extraction and ethanol precipitation, as previously described (30). DNA from the fresh frozen tissue was isolated by proteinase K digestion, followed by precipitation with a saturated NaCl solution and ethanol as previously described (31).

Somatic mutation analysis of the APC gene

APC mutation analysis was performed using the protein truncation test (PTT) for exon 15, as previously reported (30). Briefly, APC exon 15 was divided into four overlapping fragments that were amplified by polymerase chain reaction (PCR) and, subsequently, in vitro transcription and translation were performed using a TnT T7-coupled reticulocyte lysate system (Promega, Madison, WI, USA). In negative cases, the mutational cluster region was subsequently analyzed by automated sequencing in order to search for missense mutations. For the samples obtained from paraffin-embedded tissues, APC mutations were analyzed by single-strand conformational polymorphism (SSCP) or by automated sequencing (32).

Somatic mutation analysis of catenin beta 1 (CTNNB1)

Genomic DNA from each tumor sample was amplified by PCR for SSCP analysis of exon 3 of the CTNNB1 gene. The amplified products were analyzed in a mutation detection enhancement (MDE) gel and visualized by silver staining (33).

Somatic mutation analysis of the AXIN2 gene

AXIN2 mutation analysis was performed by amplification of a repetitive sequence containing the (G)7, (C)6 and (C)5 tracts (where a considerable mutation frequency was described) (34), followed by electrophoresis in 7% polyacrilamide gel containing formamide and urea and visualization by silver staining (33).

Somatic mutation analysis of BRAF, KRAS and neuroblastoma RAS viral (v-ras) oncogene homolog (NRAS) genes

BRAF (exon 15: forward primer 5′-TCATAATGCTTG CTCTGATAGGA-3′; reverse primer 5′-GGCCAAAAATTTAATCAGTGGA-3′, KRAS (exon 2: forward primer 5′-GTGTGACATGTTCTAATATAGTCA-3′; reverse primer 5′-GAATGGTCCTGCACCAGTAA) (35) and NRAS (exons 2 and 3-primers were kindly provided by Dr Branca Cavaco), were amplified by PCR. The DNA samples were amplified in a standard PCR buffer (Invitrogen, Waltham, MA, USA). Mutations in these genes were analyzed by automated sequencing.

Sequencing analysis

After amplification, PCR products were purified with Illustra GFX™ PCR DNA and Gel Band purification kit (GE Healthcare, Little Chalfont, UK) according to the manufacturer's instructions. Sequencing reactions were performed using the BigDye Terminator Cycle Sequencing kit and the respective products were analyzed on the ABI PRISM™ 310 Genetic Analyzer (both from Applied Biosystems, Foster City, CA, USA) using Sequencing Analysis software. The pathogenic relevance of missense variants was evaluated by comparing aminoacid sequences using PolyPhen software (http://genetics.bwh.harvard.edu/pph/) and SIFT software (http://sift.jcvi.org/).

MSI/loss of heterozygosity (LOH) analysis

MSI status was analyzed using the Bethesda panel of reference markers (36). Each colonic lesion and paired normal DNA were amplified by PCR for each of the microsatellite markers and analyzed in the ABI Prism™ 310 Genetic Analyzer using GeneScan software (Applied Biosystems). The lesions were classified as MSI-high (H) when showing MSI in two or more of the five markers, MSI-low (L) when MSI was detected in one of the markers, and MSS when none of the markers revealed instability (37). In cases exhibiting MSI-L, BAT-40 and MYCL markers were also analyzed and the lesions were classified as MSI-H when MSI was detected in >40% of the 7 markers analyzed; otherwise they were classified as MSI-L, as previousy described (37).

A total of 4 dinucleotide markers flanking MGMT (D10S1703, D10S1676, D10S169 and D10S1651) were analyzed for each colonic lesion and paired normal DNA in order to evaluate the presence of LOH. Each lesion was subsequently scored as demonstrating LOH if the ratio between the areas of the normal and the tumor alleles was >1.5 or <0.67.

Regarding the D5S346 marker, LOH was evaluated (and confirmed using the D5S1965 marker) as indicative of loss of the APC gene. LOH of D2S123 and D17S250 was also evaluated as described above.

Methylation analysis

The analysis of MGMT and mismatch repair (MMR) gene promoter methylation was performed by methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA) (38) using the SALSA MS-MLPA KIT ME011 MMR, (MRC-Holland, Amsterdam, The Netherlands). MS-MLPA reactions were performed as described by the manufacturer. The samples were analyzed using GeneScan software on the ABI Prism™ 310 Genetic Analyzer (Applied Biosystems). The results were normalized using MRC Coffalyser MLPA-DAT software v.9.4 (MRC-Holland). A ratio of 0.15 or higher, corresponding to 15% of methylated DNA, was indicative of promoter methylation as described elsewhere (32,39).

Statistical analysis

Fisher's exact test (using a two-sided or 2×3 table) and the χ2 test (http://www.quantitativeskills.com/sisa/index.htm) were used to compare categorical variables, and the Student's t-test (http://www.physics.csbsju.edu/stats/t-test.html) was used to compared continuous variables. A p-value <0.05 was considered to indicate a statistically significant difference.

Results

Clinical characterization

Table I summarizes the clinical features of the 18 patients included in this study, stratified into two groups: SPP-FHP/CRC and sporadic SPP. The average age at diagnosis (i.e. the age at which they presented symptoms) among our cohort of SPP patients (n=18) was 55±11 years (range 25–80); however, it was significantly higher in the SPP-FHP/CRC group than in the sporadic SPP group [60±10 years (range 41–80) vs. 46±15 years (range 25–68), p=0.027 (Student's t-test)] (Table II).

Table I Clinical features of the patients evaluated in this study, histological characterization of the respective lesions and family history of SPP and/or polyps/CRC in first-degree relatives.

Table I

Clinical features of the patients evaluated in this study, histological characterization of the respective lesions and family history of SPP and/or polyps/CRC in first-degree relatives.

Family	Patient ID	Age at diagnosis in years	Gender	Total number of lesions	Type of lesionsa	Preferential location of lesionsb	CRC	WHO diagnostic criteriac	No. of affected individuals in the family	Family historyd (age at diagnosis in years)
SPP-FHP/CRC
PH1	A756	62	M	>100	HP+TALGD+TSALGD+SSA	Whole colone	No	3	3	Son, >45 SE polyps (42); Son, 2 SE polyps (37)
PH3	A755	41	F	>100	HP+TSALGD+TVALGD+SSA+TALGD	Whole colone	No	3	3	Mother, CRC (67); maternal aunt, CRC (58)
PH4	CA638	66	M	19	TSA (LGD+HGD)+VA	Whole colon	Yesf	1	5	Twin brother, 20 AD and SE polyps (70); son, 2 AD polyps (37); nephew, 18 AD polyps (54)
	CA636	69	M	50	HP+TALGD+TSALGD+TVALGDg	Proximal	Yesf	3
PH5	A193	69	F	40	HP+TALGD+TVAHGD	Proximal	Yes	3 plus 1	3	Sister, 2 AD polyps (67); son, 1 SE polyp (52)
PH6	A478	64	M	50–100	HP+TSALGD+TALGD+SSA	Distale	No	3 plus 1	5	Father, CRC (57); sister, 7 polyps (61); daughter, 1 SE polyp (39); son, 2 AD polyps (35)
PH7	A759	50	M	50–100	HP+TA	Whole colon	Yes	3	3	Mother, 2 AD polyps (75); brother, 8 SE and AD polyps (47)
PH8	A760	59	F	45	HP+SSA+TSALGD	Proximal	No	1 plus 3	4	Maternal grandfather, CRC; mother, CRC (73); sister, 3 AD polyps (61)
PH12	A758	57	M	40	HP	Distal	Yes	3	2	Brother, 1 AD polyp (44)
PH14	A686	80	M	49	HP+TSALGD+TALGD	Distal	No	3	4	Daughter, 2 SE polyps (54); daughter, 11 SE and 1 AD polyps (42); son, 1 AD polyp (44)
PH19	A993	58	F	17	HP+TALGD	Distal	No	1	3	Mother, CRC; sister, 6 polyps (68)
PH33	A983	49	M	45	HP+TSALGD+TALGD+SSA	Distal	No	1 plus 3	4	Paternal uncle, polyps (69); father, 1 AD polyp (77); brother, 1 AD polyp (50)
Sporadic SPP
PH9	A500	48	F	40	HP+SSA+TSALGD	Whole colon	No	1 plus 3	1	-h
PH10	A989	25	F	<100	HP	NA	Yes	3 plus 1	1	-h
PH11	A757	53	M	50	HP+TSA	Distal	Yesf	3	1	-h
PH16	A990	68	M	15	HP+SSA	Whole colon	No	1	1	-h
PH18	A992	46	F	10	TSALGD+HP	Distal	No	1	1	-h
PH22	A951	33	F	31	HP+TALGD	Distal	No	1 plus 3	1	-h

a The type of lesion(s) that was prevalent (≥70%) in each patient is indicated in bold.

b We considered a proximal or distal preferential location of the lesions when at least 70% of the lesions (majority serrated) were located in the proximal or distal colon, respectively.

c WHO clinical criteria for the identification of serrated polyposis (SPP), as revised in 2010: i) At least five serrated polyps proximal to the sigmoid colon, two of which are greater than 10 mm in diameter. ii) Any number of serrated polyps occurring proximal to the sigmoid colon in an individual who has a first-degree relative with SPP iii) More than 20 serrated polyps of any size distributed throughout the colon.

d AH families showed a dominant inheritance pattern with the exception of PH12, that revealed a recessive pattern.

e The polyps are larger in the proximal colon.

f Adenomatous/serrated carcinoma (AD/S);

g with areas of traditional serrated adenoma (TSA).

h No evidence of SPP and/or polyps/CRC was found in first-degree relatives of the sporadic SPP patients, either by regular colonoscopy examination or by absence of symptoms. CRC, colorectal cancer; M, male; F, female; HP, hyperplastic polyp; TALGD, tubular adenoma with low grade dysplasia; TSALGD, traditional serrated adenoma with low grade dysplasia; TVAHGD, tubulovillous adenoma with high grade dysplasia; SSA, sessile serrated adenoma; SE, serrated; TVALGD, tubulovillous adenoma with low grade dysplasia; LGD, low grade dysplasia; HGD, high grade dysplasia; VA, villous adenoma; AD, adenomatous; TA, tubular adenoma; NA, not available; FHP, family history of SPP.

Table II Comparison between clinical features in patients with sporadic SPP and those with SPP-FHP/CRC.

Table II

Comparison between clinical features in patients with sporadic SPP and those with SPP-FHP/CRC.

Clinical feature	SPP-FHP/CRC	Sporadic SPP	p-value
Age at diagnosis (years)	60±10	46±15	0.027 (Student's t-test)
Preferential location of lesions
Whole colon	4/12 (33%)	2/5 (40%)	NS
Proximal	3/12 (25%)	0/5	NS
Distal	5/12 (42%)	3/5 (60%)	NS
≥40 lesions	10/12 (83%)	3/6 (50%)	NS
AD lesions	10/12 (83%)	1/6 (17%)	0.013a
≥3 types of lesions	9/12 (75%)	1/6 (17%)	0.032a

{ label (or @symbol) needed for fn[@id='tfn9-ijmm-38-03-0687'] } Statistically significant values are shown in bold. NS, non-significant (p>0.05).

a Fisher's exact test (two-sided). AD, adenomatous; SPP, serrated polyposis; SPP-FHP/CRC, SPP associated with a family history of SPP and/or polyps/colorectal cancer (CRC) (multiple or diagnosed at a young age) in first-degree relatives.

The number of lesions was higher in the SPP-FHP/CRC group than in the sporadic SPP group (threshold, ≥40 lesions): [10/12 (83%) vs. 3/6 (50%) patients, respectively]. With respect to histological features, AD lesions were more frequent in the SPP-FHP/CRC group than in the patients with sporadic SPP [10/12 (83%) vs. 1/6 (17%), p=0.013]. Moreover, the patients with SPP-FHP/CRC presented a more heterogeneous spectrum of lesions in comparison with the patients with sporadic SPP. In agreement with these findings, the presence of three or more types of lesions was more frequent in the former group [9/12 (75%) vs. 1/6 (17%), p=0.032].

Regarding the location of the lesions in each patient, we observed that whereas some of the patients with SPP presented lesions dispersed uniformly throughout the whole colon, other patients with SPP presented a predominance of lesions in one of the two major segments, proximal or distal. Therefore, a prevalence of proximal or distal location of the lesions was considered when at least 70% of the lesions (majority SE) were located in the proximal or distal colon, respectively. In accordance, a preferential proximal location was observed in 3/12 (25%) of the SPP-FHP/CRC patients and in none of the patients with sporadic SPP (0/5). A preferential distal location was observed in 3/5 (60%) of the sporadic SPP patients and in 5/12 (42%) of the patients with SPP-FHP/CRC.

Molecular characterization

The molecular alterations found in each SPP-FHP/CRC lesion, namely mutations in RAS/RAF and Wnt signaling genes, MSI, MGMT and MMR methylation, LOH of MGMT locus and LOH at D2S123 and D17S250 markers, are presented in Table III. The spectra of these molecular alterations led us to observe that the somatic mutation/promoter hypermethylation spectra differs between those patients whose lesions were preferentially located in the proximal colon, or distributed throughout the whole colon, and those whose lesions were preferentially located in the distal colon, as shown in Table IV. This led us to stratify the patients with SPP-FHP/CRC into two groups, proximal/whole-colon and distal SPP-FHP/CRC.

Table III Results of the molecular analysis of SE and AD lesions from patients with SPP.

Table III

Results of the molecular analysis of SE and AD lesions from patients with SPP.

A, Results of the molecular analysis of SE and AD lesions from patients SPP-FHP/CRC
Family	Patient ID	Lesion ID	Type of lesion	Location of lesions	MSI	D2S123, D17S250 LOH	LOH of MGMT locus	Mutations					Promoter methylation
								APC	CTNNB1	AXIN2	BRAF	KRAS	MGMT	MMR genes
Preferential location of lesions - proximal/whole-colon
PH1	A756	A756AS	TSALGD	NA	MSS′	NC, NC	Yes	c.4099C>T (p.Q1367X)	N	N	–	N	M	MSH6
		A756AT1	TALGD	NA	MSS′	NC, N	No	c.4123C>T (p.H1375Y)	N	N	N	N	M	MSH6
		A756AT2	TALGD	NA	MSS′	NC, N	IC	c.4123C>T (p.H1375Y)	N	N	N	N	NM	NM
		A756PH1	HP	NA	MSS′	NC, NC	Yes	N	N	–	N	N	M	MSH6, MSH3
		A756PH2	SSA	NA	MSS′	NC, N	IC	c.4289delC (p.T1430TfsX43)	N	N	–	N	M	MSH6
PH3	A755	A755AS1	TSALGD	Distal	MSI-H	NI, D17S250	IC	NC	N	N	c.1785T>G (p.F595C)	N	–	–
		A755AS2	TSA	Proximal	MSI-L	NI, D17S250	IC	c.4235G>A (p.G1412E)	c.115G>A (p.A39T)	N	c.1799T>A (p.V600E)	N	M	MSH6
		A755AS3	TSALGD	Proximal	MSI-H	NI, NI	Yes	NC	N	N	N	N	NM	MSH6
		A755PH1	HP	Proximal	MSI-L	NI, D17S250	Yes	N	N	N	N	N	M	MSH6
		A755PH2	SSA	Proximal	MSI-L	D2S123, D17S250	IC	N	N	N	N	N	NM	NM
PH4	CA638	CA638AS	TSALGD	Distal	MSS	N, N	No	N	c.122C>T (p.T41I)	N	N	c.35G>C (p.G12A)	M	MSH3
		CA638C	Ca (AD/S)	Rectum	MSS	N, N	No	LOH	N	N	N	c.35G>A (p.Gl2D)	M	NM
	CA636	CA636AT1	TALGD	Proximal	MSI-L	NI, D17S250	Yes	c.4262delG (p.S1421MfsX52)	N	–	N	N	M	NM
		CA636C	Ca	Proximal	MSS	D2S123, N	Yes	NC	N	N	N	N	M	MLH3
		CA636AT2	TALGD	Proximal	MSI-L	D2S123, NI	Yes	N	N	N	N	N	NM	NM
		CA636AT3	TALGD	Proximal	MSS	D2S123, D17S250	Yes	N	N	N	c.1811G>A (p.W604X)	N	M	NM
		CA636ATV	TVALGD	Proximal	MSI-H	NI, NI	IC	c.4024T>G (p.L1342V)	N	N	N	c.38G>A (p.G13D)	M	NM
PH5	A193	A193AT	TALGD	Proximal	MSI-L	N, D17S250	IC	c.4189G>A (p.E1397K)	N	N	N	N	M	MSH6
		A193ATV	TVAHGD	Rectum	MSS	D2S123, N	Yes	c.4123C>T (p.H1375Y)	N	N	N	c.35G>A (p.G12D)	M	NM
		A193C	Ca	Proximal	MSS	D2S123, D17S250	Yes	N	N	N	N	N	M	NM
		A193PH1	HP	Proximal	MSS	D2S123, N	Yes	LOH, c.4123C>T (p.H1375Y)	N	N	N	N	M	NM
		A193PH2	HP	Proximal	MSS	D2S123, D17S250	Yes	NC	N	N	N	N	M	NM
PH7	A759	A759T	Ca	Proximal	MSI-H	NI, N	IC	N	c.133T>C (p.S45P)	c.l994delG (p.G665AfsX24)	N	c.34G>A) (p.G12S)	NM	NM
PH8	A760	A643PA	HP	Proximal	MSS	NI, N	No	N	N	N	c.1799T>A (p.V600E)	N	M	NM
		A643PB	HP	Distal	MSS	NI, N	No	N	N	N	c.1799T>A (p.V600E)	N	M	NM
		A760AS1	TSALGD	Proximal	MSS′	NC, NC	Yes	LOH	N	N	c.1799T>A (p.V600E)	N	–	–
		A760PH1	SSA	NA	MSI-L	NI, D17S250	–	c.3926_3930 delAAAGA (p.E1309DfsX2)	N	N	N	N	NM	NM
		A760PH2	SSA	Proximal	MSI-H	NI, NC	Yes	NC	N	N	N	N	–	–
		A760PH3	SSA	Proximal	MSI-L	NI, N	Yes	LOH	c.130C>T (p.P44S)	N	c.1799T>A (p.V600E)	N	NM	NM
		A760PH4	SSA	NA	MSI-L	NI, NC	Yes	LOH	N	N	N	N	NM	NM
		A760PH5	SSA	NA	MSI-L	NI, N	No	LOH	N	N	N	N	NM	NM
		A760PH6	SSA	NA	MSS	NI, N	No	LOH	N	N	N	N	NM	NM
Preferential location of lesions - distal
PH6	A478	A478PA2	HP	NA	MSS	N, N	No	N	N	N	c.1799T>A (p.V600E)	N	M	NM
		A478PB	HP	NA	MSS	N, N	–	N	N	N	c.1799T>A (p.V600E)	N	–	–
		A478PC	NCM	NA	MSS	N, N	–	N	N	N	N	c.35G>T (p.G12V)	NM	NM
		A478PD	NCM	NA	MSS	N, N	–	N	–	–	N	–	–	–
		A478PE	HCM	NA	MSS	N, N	–	N	N	N	N	c.35G>A (p.G12D)	NM	NM
		A478PF	TALGD	NA	MSS	N, N	–	N	N	N	N	N	NM	NM
		A478PG	HP	NA	MSS	N, N	No	N	N	N	c.1799T>A (p.V600E)	N	M	NM
		A478PH	HP	NA	MSS	N, N	No	N	N	N	c.1799T>A (p.V600E)	N	NM	NM
		A462PH1	SSA	NA	MSS	N, N	No	N	N	N	c.1799T>A (p.V600E)	N	M	NM
		A462PH2	SSA	NA	MSS	N, N	IC	N	N	N	c.1799T>A (p.V600E)	N	M	NM
PH12	A758	A758C	Ca	Distal	MSI-L	NI, NC	No	LOH	N	N	c.1799T>A (p.V600E)	N	M	NM
		A758PH	HP	Rectum	MSI-L	NI, D17S250	IC	LOH	N	N	c.1799T>A (p.V600E)	N	M	NM
PH14	A686	A686P1A	HP	Distal	MSS	N, N	No	N	N	N	N	c.35G>A (p.G12D)	NM	NM
		A686P2B	HP	Distal	MSS	N, N	No	N	N	N	N	c.35G>T (p.G12V)	M	NM
		A686P3C	HP	Distal	MSS	N, N	No	N	N	N	N	c.35G>A (p.G12D)	NM	NM
		A686P4D	HP	Distal	MSS	N, N	No	N	N	N	N	c.35G>A (p.G12D)	NM	NM
		A686P5E	HP	Distal	MSS	N, N	–	N	N	N	N	c.35G>T (p.G12V)	–	–
PH19	A993	A993PH1	HP	Rectum	MSS*	–	Yes	NC	c.115G>A (p.A39T)	N	c.1799T>A (p.V600E)	N	–	–
PH33	A983	A983PA	HP	Proximal	MSS*	–	No	N	N	N	c.1799T>A (p.V600E)	N	NM	NM
		A983PB	HP	Proximal	MSS*	–	No	N	N	N	c.1799T>A (p.V600E)	N	NM	NM
		A983PC	HP	Distal	MSS*	–	No	N	N	N	c.1799T>A (p.V600E)	N	NM	NM
		A983PD	TALGB	Distal	MSS*		No	c.4189G>T (p.E1397X)	N	N	N	N	NM	NM

B, Results of the molecular analysis of SE and AD lesions from patients with SPP without a family history of SPP and/or polyps/CRC in first-degree relatives
Family	Patient ID	Lesion ID	Type of lesion	Location of lesions	MSI	D2S123, D17S250 LOH	Mutations					Promoter methylation
							APC	CTNNB1	AXIN2	BRAF	KRAS	MGMT	MMR genes
Preferential location of lesions - Proximal/whole-colon
PH9	A500	A500PA1	HP	Proximal	MSS	D2S123, NI	N	N	N	c.l799T>A(p.V600E)	N	NM	MLH1
		A500PB2	HP	Proximal	MSS	N, NI	N	N	N	c.l799T>A(p.V600E)	N	NM	NM
PH16	A990	A990ASS	SSA	NA	MSS*	–	NC	N	N	N	N	M	NM
		A990PH1	HP	Rectum	MSS*	–	NC	N	N	N	N	NM	MSH3
Preferential location of lesions - Distal
PH10	A989	A989C	Ca	Distal	MSS*	–	NC	N	N	N	N	NM	NM
PH11	A757	A757AS1	SCa	NA	MSS	N, N	c.4233delT (p.S1411RfsX4)	N	N	N	N	M	NM
PH18	A992	A992AS1	TSALGB	Distal	MSS*	–	NC	N	N	c.l799T>A(p.V600E)	N	–	–
		A992AS2	TSALGB	Distal	MSS*	–	NC	N	N	N	N	–	–
PH22	A951	A951P1	HP	Rectum	MSS*	–	N	N	N	c.l799T>A(p.V600E)	N	NM	NM
		A951P2	HP	Distal	MSS*	–	N	N	N	c.l799T>A(p.V600E)	N	NM	NM

[i] SE, serrated; AD, adenomatous; MSI, microsatellite instability; LOH, loss of heterozygosity; MMR, mismatch repair; NA, not available; MSS′, microsatellite stable (missing one marker, D2S123); NC, not completed; N, no mutation; -, not performed; M, methylated; IC, inconclusive; NM, non-methylated; MSI-H, microsatellite instability high; NI, not informative; MSI-L, microsatellite instability low; NCM, normal colonic mucosa; HCM, hyperplastic colonic mucosa; SCa, serrated carcinoma; MSH, mutS Homolog; SPP, serrated polyposis; CRC, colorectal cancer. MSS*, microsatellite stable (only performed for BAT-26, due to the lack of normal tissue for this sample). APC missense mutations were not taken into account, although p.H1375Y and p.E1397K mutations have been predicted by in silico analysis to be probably pathogenic (data not shown).

Table IV Molecular characterization of lesions from patients with SPP-FHP/CRC, stratified by preferential location of the lesions in each patient.

Table IV

Molecular characterization of lesions from patients with SPP-FHP/CRC, stratified by preferential location of the lesions in each patient.

Molecular characterization	Preferential location of lesions		p-value
	Proximal/whole-colon	Distal colon
Total Wnt gene mutations	14/26 (54%)	4/20 (20%)	0.02b
Total RAS/RAF gene mutations	12/30 (40%)	18/20 (90%)	3.7×10−4b
BRAF gene mutations	7/30 (23%)	12/20 (60%)	0.0089 (χ2 test)
KRAS gene mutations	5/32 (16%)	6/20 (30%)	NS
MSIa	15/26 (58%)	2/15 (13%)	0.0059b
MMR gene methylation and/or LOH of D2S123	17/18 (94%)	0/11	3.0×10−7b
MGMT gene methylation	19/29 (65%)	7/17 (41%)	NS
LOH of MGMT locus	16/23 (70%)	1/14 (7%)	2.2×10−4b

a Except for one lesion, microsatellite instability (MSI), either microsatellite instability-low (MSI-L) or microsatellite instability-high (MSI-H), was detected only in dinucleotide microsatellite markers.

b Fisher's exact test (two-sided). SPP, serrated polyposis; CRC, colorectal cancer; SPP-FHP/CRC, SPP associated with a family history of SPP and/or polyps/CRC (multiple or diagnosed at a young age) in first-degree relatives; MMR, mismatch repair; LOH, loss of heterozygosity; MGMT, O-6-methylguanine-DNA methyltransferase. Statistically significant values are shown in bold. NS, non-significant (p>0.05).

Although the ratio between the different types of lesions in the two groups, proximal/whole-colon and distal, do not match, i.e. in the former a higher proportion of AD lesions have been analyzed [in a recent study, individuals with large and right-sided SE lesions also had significantly more AD lesions compared with those without such types of SE lesions (40)], we found differences with respect to the mutation spectrum, even considering only HPs or SSAs, which have been analyzed in both groups. Accordingly, HPs and SSAs from patients with proximal/whole-colon SPP-FHP/CRC presented RAS/RAF gene mutations less frequently [2/6 (33%) and 1/7 (14%) vs. 14/14 and 2/2, respectively, p=0.003 and p=0.08] whereas MMR gene methylation or LOH of D2S123 [flanking mutS homolog 6 (MSH6)] occurred more frequently (4/4 and 2/2 vs. 0/7 and 0/2, respectively, p=0.003 and p=0.33), when compared with the same type of lesions from distal SPP-FHP/CRC patients (Table V). Moreover, SE and AD lesions presented a similar spectrum of molecular alterations, especially among each patient. The exception were BRAF mutations that were significantly more frequent in SE lesions [17/36 (47%) vs. 2/14 (14%), p=0.05] (Table V). For each patient, either presenting proximal/whole-colon or distal SPP-FHP/CRC, the spectra of somatic molecular alterations detected in the lesions were similar regardless of the location of each specific lesion. For example, in a patient with a prevalence of proximal lesions, these presented a specific mutation pattern that was shared by the few distal lesions that were analyzed from the same patient and different from the proximal lesions from patients with a predominance of distal lesions and vice versa (Table IIIA).

Table V Molecular characterization of SPP-FHP/CRC lesions stratified by histological type of lesions and the preferential location of the lesions in each patient (proximal/whole-colon or distal).

Table V

Molecular characterization of SPP-FHP/CRC lesions stratified by histological type of lesions and the preferential location of the lesions in each patient (proximal/whole-colon or distal).

	HCM	HP	TSA	SSA	SCa	SE lesions	TA	TVA	Ca	AD lesions	SE+AD lesions
Total Wnt gene mutations
Proximal/whole-colon	–	1/4 (25%)a	4/4a	6/7(86%)a	1/1	12/16 (75%)b,c	1/6 (17%)	0/2	1/2 (50%)	2/10 (20%)b	14/26 (54%)
Distal colon	0/1	2/14 (14%)	–	0/2	–	2/17 (12%)c	1/2 (50%)	–	1/1	2/3 (67%)	4/20 (20%)
Total RAS/RAF gene mutations
Proximal/whole-colon	–	2/6 (33%)	4/5 (80%)	1/7 (14%)	1/1	8/19 (42%)d	1/6 (17%)	2/2	1/3 (33%)	4/11 (36%)	12/30 (40%)
Distal colon	1/1	14/14	–	2/2	–	17/17d	0/2	–	1/1	1/3 (33%)	18/20 (90%)
BRAF gene mutations
Proximal/whole-colon	–	2/6 (33%)	3/5 (60%)	1/7 (14%)	0/1	6/19 (32%)e	1/6 (17%)	0/2	0/3	1/11 (9%)	7/30 (23%)
Distal colon	0/1	9/14 (64%)	–	2/2	–	11/17 (65%)e	0/2	–	1/1	1/3 (33%)	12/20 (60%)
KRAS gene mutations
Proximal/whole-colon	–	0/6	1/6 (17%)	0/8	1/1	2/21 (10%)f	0/6	2/2	1/3 (33%)	3/11 (27%)	5/32 (16%)
Distal colon	1/1	5/14(36%)	–	0/2	–	6/17 (35%)f	0/2	–	0/1	0/3	6/20 (30%)
MSI
Proximal/whole-colon	–	1/5 (20%)g	3/4 (75%)g	6/7(86%)g	0/1	10/17 (59%)h	3/4 (75%)	1/2 (50%)	1/3 (33%)	5/9 (56%)	15/26 (58%)
Distal colon	0/1	1/10(10%)	–	0/2	–	1/13 (8%)h	0/1	–	1/1	1/2 (50%)	2/15 (13%)
MMR gene methylation and/or LOH of D2S123
Proximal/whole-colon	–	4/4	4/4	2/2	0/1	10/11 (91%)i	4/4	1/1	2/2	7/7	17/18 (94%)
Distal colon	0/1	0/7	–	0/2	–	0/10i	0/1	–	–	0/1	0/11
MGMT gene methylation
Proximal/whole-colon	–	6/6j	3/4 (75%)	1/7 (14%)	1/1	11/18(61%)	4/6 (67%)	2/2	2/3 (67%)	8/11 (73%)	19/29 (65%)
Distal colon	0/1	4/11 (36%)j	–	2/2	–	6/14 (43%)	0/2	–	1/1	1/3 (33%)	7/17(41%)
LOH of MGMT locus
Proximal/whole-colon	–	4/6 (67%)k	3/4 (75%)	3/5 (60%)	0/1	10/16 (63%)l	3/4 (75%)	1/1	2/2	6/7 (86%)	16/23 (70%)
Distal colon	–	1/11 (9%)k	–	0/1	–	1/12 (8%)l	0/1	–	0/1	0/2	1/14 (7%)

{ label (or @symbol) needed for fn[@id='tfn14-ijmm-38-03-0687'] } Statistically significant values are shown in bold.

a p=0.02, Fisher's exact test (2×3).

b p=0.0091, Fisher's exact test (two-sided).

c p=0.0011, Fisher's exact test (two-sided).

d p=1.3×10⁻⁴, Fisher's exact test (two-sided).

e p=0.049, Fisher's exact test (two-sided).

f p=0.062, Fisher's exact test (two-sided).

g p=0.017, Fisher's exact test (2×3).

h p=0.0049, Fisher's exact test (two-sided).

i p=3.12×10⁻⁵, Fisher's exact test (two-sided).

j p=0.017, Fisher's exact test (two-sided).

k p=0.027, Fisher's exact test (two-sided).

l p=0.0045, Fisher's exact test (two-sided). SPP, serrated polyposis; CRC, colorectal cancer; SPP-FHP/CRC, SPP associated with a family history of SPP and/or polyps/CRC (multiple or diagnosed at a young age) in first-degree relatives; MMR, mismatch repair; HCM, hyperplastic colonic mucosa; HP, hyperplastic polyp; TSA, traditional serrated adenoma; TVA, tubulovillous adenoma; SSA, sessile serrated adenoma; TA, tubular adenoma; AD, adenomatous; Ca, carcinoma; SCa, serrated carcinoma; SE, serrated; LOH, loss of heterozygosity.

The abovementioned findings led us to analyze the molecular data from the patients with SPP-FHP/CRC, who were stratified into two groups: proximal/whole-colon and distal SPP-FHP/CRC.

Proximal/whole-colon vs. distal SPP-FHP/CRC

Mutations in the Wnt genes, as well as MSI, were significantly more frequent in the patients with proximal/whole-colon SPP-FHP/CRC than in the patients with distal SPP-FHP/CRC [14/26 (54%) vs. 4/20 (20%), p=0.02; 15/26 (58%) vs. 2/15 (13%), p=0.0059] (Table IV). Interestingly, among the proximal/whole-colon SPP-FHP/CRC samples, Wnt gene mutations were significantly more frequent in the SE lesions than in the AD lesions [12/16 (75%) vs. 2/10 (20%), p=0.0091]. In the SE lesions, Wnt gene mutations, as well as MSI, were more frequent in TSAs (4/4 and 3/4) and in SSAs (6/7 and 6/7) and rarely detected in HPs (1/4 and 1/5) (p=0.02 and p=0.017, respectively) (Table V).

Similarly, LOH of the MGMT locus and MGMT methylation were also more frequent in lesions from the patients with proximal/whole-colon SPP-FHP/CRC, in comparison with lesions from the patients with distal SPP-FHP/CRC [16/23 (70%) vs. 1/14 (7%), p=2.2×10−4; 19/29 (65%) vs. 7/17 (41%), p=0.1, respectively] (Table IV). The same difference was observed even considering SE lesions only (Table V). In particular, MGMT methylation was detected in all HP lesions (6/6) from proximal/whole-colon SPP-FHP/CRC, in contrast to the lower frequency observed in HPs from distal SPP-FHP/CRC (4/11, 36%) (p=0.017).

Interestingly, among lesions which were deemed informative for methylation analysis and loss of LOH of D2S123, the presence of MMR gene methylation or of the D2S123 LOH (flanking MSH6) was only observed in proximal/whole-colon SPP-FHP/CRC lesions [17/18 (94%) vs. 0/11, p=3.0×10−7]. These alterations were found in the majority of early lesions and in all histological types (Tables IIIA and IV). It is of note that MLH1 methylation was not detected in any of the SPP-FHP/CRC lesions, being observed only in one lesion from the sporadic SPP group (Table IIIB). Moreover, it is also of note that except for one lesion, MSI, either MSI-L or MSI-H was detected only in dinucleotide microsatellite markers.

By contrast to the abovementioned molecular alterations, in the SPP-FHP/CRC samples, BRAF and KRAS mutations were more frequent in the lesions located in the distal colon than those located in the proximal/whole-colon [12/20 (60%) vs. 7/30 (23%), p=0.0089 (χ2 test) and 6/20 (30%) vs. 5/32 (16%), respectively], although the latter was not statistically significant (Table IV). Considering only the SE lesions, mutations in the RAS/RAF genes were detected in all the lesions from the distal SPP-FHP/CRC, namely in all HPs (14/14), HCM (1/1) and in one NCM (Table IIIA), but in only 8/19 (42%) lesions from the proximal/whole-colon SPP-FHP/CRC (p=1.3×10−4).

With respect to KRAS/BRAF mutations, two groups of patients were observed among those with either proximal/whole-colon or distal SPP-FHP/CRC: one group whose lesions presented KRAS mutations (PH4, PH5, PH7 and PH14) and another group, whose lesions presented BRAF mutations (PH3, PH8, PH19 and PH33) (Table IIIA). One patient presented either BRAF- or KRAS-positive lesions (family PH6). Notably, CRC was more frequent in the patients with proximal/whole-colon SPP-FHP/CRC associated with KRAS mutations than in the remaining patients [4/4 vs. 1/8 (12%), p=0.01] (Tables I and IIIA).

Discussion

SPP-FHP/CRC and sporadic SPP differ at the clinical level

The patients with SPP-FHP/CRC and sporadic SPP differed with respect to clinical and histological features. The older mean age at diagnosis (60 vs. 46 years old) of the former may underlie a slower process of tumorigenesis. This is in contrast to that which has been observed in relation to other hereditary CRC syndromes, namely in familial adenomatous polyposis and in Lynch syndrome, which are diagnosed at an earlier age (usually ≤50 years old) compared to the age at diagnosis in patients with sporadic CRC (>60 years old) (32,41). The presence of a more heterogeneous histological pattern of lesions in patients with SPP-FHP/CRC, associated with the concomitant presence of both SE and AD lesions, compared with the lesions in patients with sporadic SPP, suggests the involvement of other pathways in the tumorigenic process associated with SPP-FHP/CRC, in addition to the serrated pathway of tumorigenesis.

Molecular alterations involved in tumor initiation distinguish between two forms of SPP-FHP/CRC: proximal/whole-colon and distal

Two forms of SPP-FHP/CRC appear to exist according to the preferential location of the lesions in the colon and rectum, proximal/whole-colon and distal, which differ with respect to the somatic events involved in tumor initiation. LOH and methylation of MGMT, MMR gene methylation and/or LOH of D2S123 and Wnt gene mutations appear to be the major somatic events that lead to tumor initiation in proximal/whole-colon SPP-FHP/CRC. By contrast, in distal SPP-FHP/CRC, KRAS or BRAF mutations were found in the majority of early lesions and thus seem to play a major role in tumor initiation.

We have previously shown that distinct Wnt gene mutations are selected in sporadic and hereditary CRC according to tumor location, i.e. proximal or distal colon (33,42). We and others have also proposed that this finding is the result of the selection of a specific level of β-catenin signaling, optimal for tumor formation, which differs along the colorectum, thus contributing to differences in lesion distribution in specific types of CRC, such as Lynch syndrome (42,43). Proving this, variable gradients in the number of stem cells and physiological Wnt activity have been demonstrated throughout the length of the intestinal tract (44). Thus, in a similar fashion, tumorigenic pathways may also differ between proximal and distal SPP-FHP/CRC.

MGMT and MMR alterations, followed by Wnt gene mutations, are involved in the initiation of proximal/whole-colon SPP-FHP/CRC

The exclusive detection of MMR gene methylation (mainly of MSH6) and/or LOH of D2S123 (flanking MSH6) in proximal/whole-colon SPP-FHP/CRC, in the majority of early lesions and in all histological types, appears to suggest that the MMR system plays an important role in the initiation of proximal/whole-colon SPP-FHP/CRC, which is in agreement with the high frequency of MSI (either MSI-L or MSI-H) in these lesions (58%). Interestingly, MMR methylation and, consequently, MMR deficiency were not associated with MLH1 methylation as has been previously observed in sporadic SE lesions located in the proximal colon (7), but rather with MSH6 or mutS homolog 3 (MSH3) methylation. Accordingly, a high frequency of LOH of the MSH3 locus has been recently described in sporadic MSI-L CRC, suggesting that the impairment of other MMR genes such as MSH3 or MSH6, as observed in the present study, are involved in an MSI-L pathway, instead of MLH1, which is usually associated with the MSI-H serrated pathway (45). The detection of MSI almost exclusively in dinucleotide microsatellite markers is in agreement with this finding, since this type of MSI has been described to be a characteristic feature of MSI-L tumors (46). Interestingly, in the present study, MSI was detected more frequently at D2S123 followed by D17S250.

MGMT methylation and LOH of the MGMT locus were the most frequent alterations in proximal/whole-colon SPP-FHP/CRC, and MGMT methylation was detected in all HPs, commonly known as the precursor lesion (12). Therefore, we suggest that, similarly to MMR alterations, LOH and methylation of MGMT may also be early events in SPP-FHP/CRC proximal/whole-colon tumorigenesis. Notably, among the 17 lesions informative for both MMR and MGMT alterations in this form of SPP-FHP/CRC, in 16 (94%) both events were noted (Table IIIA). It is known that MGMT deficiency results in the inability to repair O6-methylguanine in the DNA, caused by genotoxic stress, which, once accumulated, leads to the translocation of the MutSα complex (MSH2 and MSH6) into the nucleus, thus increasing GT mismatch binding activity (47). This may lead to a selective pressure for molecular changes that impair MSH2 or MSH6 function such as promoter hypermethylation or LOH, thus explaining the association between the latter and MGMT methylation in the same early SPP-FHP/CRC lesions. Thus, we suggest a primary role for MGMT methylation, O6-methylguanine errors and MMR alterations in tumor initiation of proximal/whole-colon SPP-FHP/CRC. We further suggest that this molecular signature may indicate that a germline defect in the mechanisms regulating the response to genotoxic stress underlies the genetic susceptibility in this form of SPP-FHP/CRC.

In the present study, the higher frequency of Wnt gene mutations in proximal SPP-FHP/CRC, particularly in SE lesions, when compared with the AD lesions, suggests that this pathway also plays an important role in this form of SPP-FHP/CRC, especially in the transition to SE adenoma since this frequency was significantly higher in TSA and SSA than in HP and HCM (p=8.4×10−4). In agreement, CTNNB1 or AXIN2 mutations, that are selected almost exclusively in proximal colorectal tumors with MSI (33), were detected in 4/14 (28%) TSAs and SSAs from proximal/whole-colon SPP-FHP/CRC. Moreover, among APC nonsense and missense mutations, the majority (7/8; 88%) were of the transition type which is a characteristic feature of cells presenting MMR defects (48–50).

The occurrence of LOH of D2S123 and/or D17S250 dinucleotide marker in the present study [17/48 (35%) and 7/51 (14%), respectively], has been previously described in Paneth cell metaplasia, a condition that is commonly observed in the small intestine and the proximal colon of elderly individuals (51,52). Therefore, MGMT deficiency may make these cells more exposed to genotoxic stress, thus leading to molecular changes in Wnt genes and consequently to commitment to Paneth cell lineage [to which Wnt gene mutations largely contribute (53)] and to Paneth cell metaplasia. Therefore, colonic mucosa with Paneth cell metaplasia may be one of the pre-neoplastic lesions in the development of proximal/whole-colon SPP-FHP/CRC.

BRAF and KRAS mutations play different roles in proximal and distal SPP-FHP/CRC

Our finding that patients with proximal/whole-colon or distal SPP-FHP/CRC may carry, preferentially, either KRAS or BRAF mutations, supports previous observations suggesting that different forms of SPP exist, depending on whether lesions follow a KRAS or a BRAF pathway (22).

In addition, in the present study, we noted distinct roles for these mutations between proximal and distal SPP-FHP/CRC. BRAF or KRAS mutations were detected in the majority of distal SPP-FHP/CRC lesions, mostly SE early lesions, thus underlining their importance in early stages, whereas in proximal/whole-colon SPP-FHP/CRC these mutations (mainly of KRAS) appear to be more important in tumor progression (mostly detected in TSAs, TVAs and Cas). Accordingly, a KRAS or alternate pathway has been proposed to be involved in the transition from TSA or TVA to CRC in SPP (10). Indeed, in patients with proximal/whole-colon SPP-FHP/CRC, KRAS mutations were found only in TSAs, TVAs or Cas (PH4, PH5 and PH7) which is in accordance with their association with the development of a villous architecture and hence with malignant transformation (10,54–56). Therefore, as TSAs and TVAs shared early somatic events with HPs and TAs, respectively, from the same patients, and based on the model of SPP tumorigenesis previously presented by Leggett and Whitehall (10), we propose that proximal/whole-colon SPP-FHP/CRC tumorigenesis may follow an alternate or KRAS pathway, where TVA and TSA may develop from TA and HP, respectively, finally leading to CRC, that may or may not present with MSI (Fig. 1A, upper panel). Alternatively, a serrated or BRAF pathway (families PH3 and PH8) where SSA or TSA will probably lead to MSI-H cancer carrying BRAF mutations may also occur (Fig. 1B, upper panel). In this model, a deficient DNA repair pathway characterized by MGMT and MMR gene methylation and/or LOH followed by Wnt gene mutations, appears to be predominant in proximal SPP-FHP/CRC (Fig. 1, upper panel).

Figure 1 Proposed pathways for colorectal tumorigenesis in proximal/whole-colon (upper panel) and distal serrated polyposis (SPP) associated with a family history of SPP and/or polyps/colorectal cancer (SPP-FHP/CRC) (bottom panel). Both of these forms may follow a KRAS (alternate) or a BRAF (serrated) pathway, (A and B), respectively, in the upper and lower panels. In addition, in distal SPP, an adenomatous polyposis coli (APC) (traditional) pathway may also occur [(C) in bottom panel]. Each lesion or molecular alteration in these proposed pathways is hypothesized based on the results obtained in the present study and we do not exclude that, in some cases, some of these molecular alterations may not occur, or even that other molecular alterations may also be found. The steps involving lesions that were not analyzed in this study and about which we have previously published information are represented by broken arrows. In some pathways a broken line was used to represent the increase in microsatellite instability (MSI) with tumor progression, to suggest a lower frequency in those cases. Ca, carcinoma; H P, hyperplastic polyp; MMR, mismatch repair; SSA, sessile serrated adenoma; TA, tubular adenoma; TSA, traditional serrated adenoma; TVA, tubulovillous adenoma.

In distal SPP-FHP/CRC, either KRAS (PH6 and PH14) or BRAF (PH6, PH12, PH19 and PH33) mutations play a major role in tumor initiation, either through an alternate or a serrated pathway (Fig. 1A and B, bottom panel, respectively). Wnt gene mutations and MMR defects were detected in the only carcinoma presented by these patients and thus are likely involved in tumor progression. As PH6 and PH33 also presented TAs and did not present TVAs, we hypothesize that, in distal SPP-FHP/CRC, some AD lesions may also develop through a traditional pathway initiated by APC mutations (Fig. 1C, bottom panel).

CRC is more frequent in patients with proximal/whole-colon SPP-FHP/CRC with TSAs, TVAs and KRAS mutations

The association of KRAS mutations in TSA or TVA with the development of CRC in proximal/whole-colon SPP-FHP/CRC suggests a higher contribution of the alternate pathway in the development of CRC in patients with SPP-FHP/CRC. Supporting our hypothesis, KRAS mutations have been previously described as more prevalent than BRAF mutations in a series of SE carcinomas occurring in the sporadic context, mainly in those presenting adjacent serrated adenomas (51%) (57). Moreover, in the same study, SE carcinomas were frequently MSS and presented a higher frequency of MGMT loss compared with traditional carcinomas, which is in agreement with our findings demonstrating that MGMT deficiency plays a prominent role in SPP-FHP/CRC, mainly in the proximal colon.

The findings that KRAS and BRAF mutations promote serrated and hyperplastic features, despite being incapable of initiating colonic adenoma development by themselves (58,59), may contribute to the apparent lower incidence of CRC in distal SPP-FHP/CRC, as according to the results of our present study, KRAS or BRAF mutations appear to be the initial molecular events in this form. However, additional studies involving more families are warranted.

In conclusion, SPP-FHP/CRC appears to be a distinct clinical and histological entity differing from sporadic SPP. However, we suggest that two forms of SPP-FHP/CRC appear to exist, proximal/whole-colon and distal, which differ mainly in the molecular alterations detected in early lesions. We further propose that a germline defect in the mechanisms regulating the response to genotoxic damage may underlie the genetic susceptibility in the former. In addition, our results suggest that CRC appears to develop more frequently in proximal/whole-colon SPP-FHP/CRC following an alternate KRAS pathway, thus underlining the importance of a complete clinical, histological and molecular characterization for CRC risk evaluation in further studies involving families with SPP. The results of these studies may be used to design appropriate guidelines for the clinical management of proximal and distal colonic presentations of SPP that assumes major relevance considering the increased risk of CRC and/or polyps in first-degree relatives.

Abbreviations:

Acknowledgments

The authors thank all the patients who participated in this study, Dr Inês Francisco for the DNA extraction and Dr Branca Cavaco for the primers for the NRAS gene. This study was sponsored and financed by a grant from Núcleo Regional do Sul, Liga Portuguesa Contra o Cancro, Terry Fox (NRS/LPCC-Terry Fox), and Fundação para a Ciência e Tecnologia (FCT), POCI/SAU-OBS/56921/2004.

References